Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SER-287 in mild-to-moderate ulcerative colitis
NCT03759041Phase 2Terminated
- Sponsor
- Seres Therapeutics
- Start
- Dec 2018
- Primary completion
- May 2021
- Modality
- Live Biotherapeutic Products
- Countries
- 2
01
Overview
A Phase 2 trial of SER287 in ulcerative colitis (UC), sponsored by Seres Therapeutics. Started Dec 2018; status: terminated.
02
Drugs
SER287
03
Conditions
ulcerative colitis (UC)
Beyond the preview
Go deeper on NCT03759041.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03759041.